6-Methoxyflavone

Synonyms: 6-甲氧基黄酮
6-Methoxyflavone 是一种口服活性的甲氧基黄酮,通过抑制 TLR4/MyD88/p38 MAPK/NF-κB 依赖途径并激活 HO-1/NQO-1 信号通路来抑制小胶质细胞中的神经炎症,通过 CCNA2/CDK2/p21CIP1 信号通路在 HeLa 细胞中诱导 S 期阻滞,抑制 NFAT 向细胞核的转位并抑制 T 细胞激活,部分恢复小鼠慢性乙醇诱导的行为缺陷,拮抗慢性缩窄损伤和糖尿病相关的神经病理性疼痛表达,可用于癌症、炎症和神经系统疾病研究。
产品编号: MS-G45285 纯度: 99.73% CAS No.: 26964-24-9 分子式: C16H12O3 分子量: 252.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

6-Methoxyflavone 是一种口服活性的甲氧基黄酮,通过抑制 TLR4/MyD88/p38 MAPK/NF-κB 依赖途径并激活 HO-1/NQO-1 信号通路来抑制小胶质细胞中的神经炎症,通过 CCNA2/CDK2/p21CIP1 信号通路在 HeLa 细胞中诱导 S 期阻滞,抑制 NFAT 向细胞核的转位并抑制 T 细胞激活,部分恢复小鼠慢性乙醇诱导的行为缺陷,拮抗慢性缩窄损伤和糖尿病相关的神经病理性疼痛表达,可用于癌症、炎症和神经系统疾病研究。

生物实验数据

生物活性 6-Methoxyflavone is an orally active methoxyflavone that inhibits neuroinflammation in microglia by suppressing the TLR4/MyD88/p38 MAPK/NF-κB-dependent pathway and activating the HO-1/NQO-1 signaling pathway, induces S-phase arrest in HeLa cells via the CCNA2/CDK2/p21CIP1 signaling pathway, inhibits NFAT nuclear translocation and T cell activation, partially restores chronic ethanol-induced behavioral deficits in mice, antagonizes chronic constriction injury- and diabetes-associated neuropathic pain expression, and can be used for research on cancer, inflammation, and neurological diseases.
体外研究
(In Vitro)

6-Methoxyflavone (20-160 μM,24-72 小时) 抑制 HaCaT、HeLa、C33A 和 SiHa 细胞的增殖,其中 HeLa 细胞最为敏感(IC50:24 小时为 94.05 μM,48 小时为 62.24 μM,72 小时为 52.12 μM)。
6-Methoxyflavone (20-160 μM,48 小时) 以浓度依赖方式在 HeLa 细胞中诱导 S 期阻滞。
6-Methoxyflavone (65 μM,48 小时) 通过 CCNA2/CDK2/p21CIP1 途径下调 HeLa 细胞中 CCNA2 和 CDK2 的 mRNA 和蛋白表达,同时上调 CCND1、CCNE1、CDK6 和 p21CIP1 的表达。
6-Methoxyflavone (3-30 μM,预处理 1 小时) 抑制 LPS 诱导的 BV2 小胶质细胞中 NF-κB p65、IκB 的磷酸化,降低 LPS (MS-X54539) 诱导的 TLR4、MyD88 表达以及 p38 MAPK、JNK 的磷酸化。
6-Methoxyflavone (3-30 μM,预处理 1 小时) 在 LPS 刺激的 BV2 小胶质细胞中抑制 TLR4/MyD88/p38 MAPK/NF-κB 依赖途径,并激活 HO-1/NQO-1 信号通路。
6-Methoxyflavone (5-20 μM,1-24 小时) 抑制 CNS-9 的增强子活性,降低 EL4 T 细胞和原代 Th2 细胞中 IL-10 的表达。
6-Methoxyflavone (5-20 μM,1-72 小时) 抑制 Th2 细胞及体外 CD4+ T 细胞中 NFAT1 向细胞核的转位,抑制从特应性皮炎小鼠分离的 CD4+ T 细胞和 CD19+ B 细胞的增殖,并减少 B 细胞的 IgE 产生。

Cell Cycle Analysis

Cell Line: HeLa cells
Concentration: 20, 40, 80, 120, 160 μM
Incubation Time: 48 h
Result: Induced S-phase arrest in HeLa cells in a concentration-dependent manner.

Cell Cycle Analysis

Cell Line: HeLa cells
Concentration: 65 μM
Incubation Time: 48 h
Result: Downregulated mRNA expression of CCNA2 and CDK2.
Upregulated CCND1, CCNE1, CDK6, and p21CIP1 in HeLa cells.

ELISA Assay

Cell Line: LPS-stimulated BV2 microglia
Concentration: 3, 10, 30 μM
Incubation Time: Pretreatment for 1 h
Result: Decreased the levels of pro-inflammatory factors (IL-1β, IL-6, TNF-α, PGE2) in LPS-stimulated BV2 microglia.

Western Blot Analysis

Cell Line: LPS-stimulated BV2 microglia
Concentration: 3, 10, 30 μM
Incubation Time: Pretreatment for 1 h
Result: Suppressed LPS-induced phosphorylation of NF-κB p65 and IκB.
reduced LPS-induced expression of TLR4, MyD88 and phosphorylation of p38 MAPK, JNK.
Decreased iNOS and COX-2 expression.
Increased HO-1 and NQO1 expression.
体内研究
(In Vivo)

6-Methoxyflavone (25-75 mg/kg,口服,在乙醇处理前 15 分钟每日一次,24 天) 部分恢复小鼠慢性乙醇诱导的行为缺陷。
6-Methoxyflavone (10-30 μM,预处理 1 小时,处理 24 小时) 对斑马鱼胚胎无毒性,并抑制 LPS 诱导的 NO 生成。
6-Methoxyflavone (25-50 mg/kg,腹腔注射,在 LPS 注射前 3 小时每日一次,持续 4 天) 防止小鼠前额叶皮层和黑质中 LPS 诱导的小胶质细胞增生。
6-Methoxyflavone (25-75 mg/kg,腹腔注射,术后每日一次,持续 21 天) 拮抗大鼠慢性缩窄损伤 (CCI) 和 Streptozotocin (STZ) (MS-Q80520) 诱导的后爪静态(压力)和动态(轻刷)痛觉过敏、热/冷和压力痛觉过敏。
6-Methoxyflavone (20-100 mg/kg,灌胃给药,每周五次,持续 6 周) 改善 BALB/c 小鼠实验性特应性皮炎的症状。

Animal Model: Male BALB/c mice (22–28 g) were used, with chronic ethanol-induced cognitive impairment models established by oral administration of 25% w/v ethanol (2.0 g/kg daily) for 24 consecutive days, followed by 6 days of ethanol withdrawal
Dosage: 25, 50, 75 mg/kg
Administration: p.o. once daily 15 min before ethanol for 24 days
Result: Restored locomotor activity suppressed by chronic ethanol and enhanced activity during abstinence and post-withdrawal.
Improved novel object recognition, with increased exploration time on days 12, 24, during abstinence, and post-withdrawal.
Enhanced Morris water maze performance.
Ameliorated Y-maze deficits and enhanced nest-building.
Increased socialization, with all doses raising exploration time with novel juveniles at all stages.
Raised frontal cortical dopamine and vitamin C and reversed frontal cortical noradrenaline reduction.
Increased hippocampal dopamine and elevated hippocampal noradrenaline.
Animal Model: 3-month-old male C57BL/6 mice were used, with LPS-induced brain inflammatory models established by intraperitoneal injection of LPS (5 mg/kg) 3 h before sacrifice, following pretreatment with 6-methoxyflavone or PBS for 4 days
Dosage: 25, 50 mg/kg
Administration: i.p. once daily for 4 days before LPS injection 3 h prior to sacrifice
Result: Reduced microglial cell density in the prefrontal cortex (PFC) and substantia nigra (SN) after LPS stimulation.
Decreased cell size of Iba1-positive microglia in PFC and SN, with 50 mg/kg showing significant effects.
Increased cell process length of microglia in PFC and SN, improving morphological abnormalities induced by LPS.
Suppressed phosphorylation of p38 in PFC and SN, inhibiting overactivation of the p38 MAPK signaling pathway.
Reduced MyD88 protein expression in SN, downregulating the TLR4/MyD88 dependent pathway.
Animal Model: Sprague-Dawley rats (male, 300-450 g) were used, with CCI-induced mononeuropathy models established by exposing the sciatic nerve and applying four double knot ligatures (1 mm apart) prior to its trifurcation
Dosage: 25, 50, 75 mg/kg
Administration: i.p. once daily for 21 days
Result: Reduced static mechanical allodynia, as evidenced by increased paw withdrawal threshold to von Frey filaments in the operated hindpaw. Alleviated dynamic mechanical allodynia, shown by prolonged paw withdrawal latency to light brushing with a cotton bud. Attenuated heat hyperalgesia.
Diminished cold allodynia.
Relieved pin-prick hyperalgesia.
Improved locomotor activity.
Enhanced motor coordination.
Showed normal gait, reflected by reduced overlap distance between forepaw and hindpaw placement in footprint analysis.
Animal Model: Sprague-Dawley rats (female, 180-220 g) were used, with STZ-induced diabetic polyneuropathy models established by a single intraperitoneal injection of streptozotocin (50 mg/kg) after 16 h fasting, and rats with random blood glucose levels exceeding 250 mg/dL 72 h post-injection were included in the experiment
Dosage: 25, 50, 75 mg/kg
Administration: i.p. once daily for 21 days
Result: Reduced static mechanical allodynia in bilateral hindpaws.
Alleviated dynamic mechanical allodynia in bilateral hindpaws.
Attenuated heat hyperalgesia in bilateral hindpaws.
Relieved static mechanical vulvodynia.
Alleviated dynamic mechanical vulvodynia.
Improved locomotor activity.
Enhanced motor coordination.
Showed normal gait, shown by reduced overlap distance between forepaw and hindpaw placement in footprint analysis.
Animal Model: BALB/c mice were used, with experimental atopic dermatitis models established by stripping the ear surface five times with surgical tape, painting with 20 μL 4% 2,4-dinitrochlorobenzene (dissolved in acetone/olive oil solution at a 1:3 ratio) for sensitization, and then challenging the ears with 20 μL 2% dinitrochlorobenzene and 20 μL dust mite extracts (10 mg/mL) dissolved in PBS containing 0.5% Tween 20 once per week for 6 weeks
Dosage: 20, 100 mg/kg
Administration: i.g. five times per week for 6 weeks
Result: Reduced infiltration of lymphocytes in the ears.
Decreased thickness of the epidermis.
Lowered serum IgE levels.
Ameliorated symptoms such as erythema, horny substance, dryness, and scaling.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 252.27
分子式 C16H12O3
CAS No. 26964-24-9
别名 6-甲氧基黄酮

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 1.06 mg/mL (4.20 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 5 mg/mL (19.82 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9640 mL19.8200 mL39.6401 mL99.1002 mL
5 mM0.7928 mL3.9640 mL7.9280 mL19.8200 mL
10 mM0.3964 mL1.9820 mL3.9640 mL9.9100 mL
15 mM0.2643 mL1.3213 mL2.6427 mL6.6067 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础